Siemens sets 2027 vote for Healthineers spin-off
Siemens plans to put the direct spin-off of Siemens Healthineers shares to a shareholder vote at its February 2027 Annual General Meeting.

Siemens plans to put a shareholder vote on the direct spin-off of Siemens Healthineers shares on the agenda for its next ordinary Annual General Meeting in February 2027.
Under the planned transaction, Siemens AG shareholders would receive Siemens Healthineers AG shares directly. The company said it is preparing the spin-off under the German Transformation Act.
The announcement follows progress since Siemens first outlined the direct spin-off structure in November 2025. Final regulatory confirmation remains outstanding, according to the company.
Siemens said it has also advanced work on the separation process. This includes preparation of the transaction and review of key contractual relationships between the companies.
In November 2025, Siemens said it planned to deconsolidate its remaining stake in Siemens Healthineers, then approximately 67%, by transferring 30% of Healthineers shares to Siemens AG shareholders.
The company said at the time that the transaction remained subject to final regulatory clarifications and approvals by the shareholder meetings of both Siemens and Siemens Healthineers.
Siemens announced plans to publicly list its healthcare business in November 2016. Siemens Healthineers later debuted on the Frankfurt Stock Exchange in 2018, with Siemens AG holding an 85% stake after the IPO, assuming full exercise of the greenshoe option.
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section

Plus Therapeutics signs AI deal with Ephemeral
The companies will develop an AI platform to integrate therapeutic, diagnostic, and bioinformatics data across Plus Therapeutics’ CNS oncology programs.

Fujifilm launches balloon-less EBUS bronchoscope
The EB-710US Ultrasound Bronchoscope is designed for pulmonary procedures and will be demonstrated at the American Thoracic Society Conference.

ACIST wins FDA clearance for Pro Diagnostic System
The Bracco company received U.S. clearance and launched ACIST Pro, a variable-rate contrast management system for image-guided cardiovascular procedures.